First NMOSD therapy gains FDA approval
- Posted on: Jul 2 2019
- Leave a response
Eculizumab (Soliris), a first-in-class complement inhibitor, is now approved for AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) following an expedited 6-month priority review.
Source: AAO
Posted in: Uncategorized